StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Free Report) in a report published on Tuesday. The firm issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Price Performance
Shares of NYSE BTX traded up $0.03 during mid-day trading on Tuesday, reaching $5.88. 481,076 shares of the company traded hands, compared to its average volume of 811,708. The firm has a market cap of $345.90 million, a PE ratio of -2.59 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a fifty-two week low of $5.10 and a fifty-two week high of $8.31. The stock has a fifty day simple moving average of $5.75 and a 200-day simple moving average of $2.39.
Brooklyn ImmunoTherapeutics Announces Dividend
The company also recently announced a monthly dividend, which was paid on Monday, March 31st. Investors of record on Friday, March 14th were paid a dividend of $0.0862 per share. The ex-dividend date was Friday, March 14th. This represents a $1.03 annualized dividend and a yield of 17.58%. Brooklyn ImmunoTherapeutics's dividend payout ratio is currently -44.05%.
Brooklyn ImmunoTherapeutics Company Profile
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Further Reading
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
